“Lymphoproliferative skin lesion as a previously unreported adverse event detected in a patient receiving mSTR TB treatment”, jpadr, vol. 3, no. 2, pp. 34–37, Jun. 2022, doi: 10.53411/jpadr.2022.3.2.7.